Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 9/20 | 0.37 |
| ▸ | CA2 | P00918 | 9/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886433 | 0.90 | GSK3B (0.37) | GSK3BADK | |
| SCHEMBL6886915 | 0.89 | GSK3B (0.43) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6885503 | 0.89 | GSK3B (0.43) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6887042 | 0.88 | GSK3B (0.42) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6880102 | 0.86 | GSK3B (0.44) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6889041 | 0.84 | GSK3B (0.42) | GSK3BADKTSHRPYGB | |
| SCHEMBL6885781 | 0.82 | GSK3B (0.52) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6887676 | 0.81 | GSK3B (0.30) | GSK3B | |
| SCHEMBL4286250 | 0.81 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6889028 | 0.81 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |